文献速递乳房整形与再造美容整形

乳房假体取出后行乳房固定术时应用皮腺体瓣自体增容的五回顾性研究

Dermoglandular flaps for autologous augmentation during mastopexy after breast implant explantation: A five-year retrospective study.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2026-07-16

这项单中心五年回顾性研究纳入75例连续患者,在假体取出同时行乳房固定术并采用皮腺体瓣自体增容,平均随访16±6个月;总体并发症率为15%,复发下垂和假性下垂/下移各占4%,取出假体体积较大可能与复发下垂相关但属探索性。

要点

  • 皮腺体瓣是假体取出后自体增容与乳房重塑的安全灵活选择
  • 总体并发症率15%,复发下垂与假性下垂/下移各4%
  • 取出假体体积较大者复发下垂风险可能升高,单期自体增容需审慎选择病例

核心结论

  • 皮腺体瓣在假体取出时行自体增容与乳房重塑安全灵活,并发症率可接受且中期稳定性满意。
  • 取出假体体积较大可能与复发下垂风险升高相关,提示部分病例单期自体增容存在潜在局限。

研究设计与样本

  • 单中心五年回顾性研究,纳入2019至2024年间75例连续接受假体取出、乳房固定术及皮腺体瓣自体增容的患者。
  • 分析人口学资料、假体特征、手术变量、并发症及结局,平均随访16±6个月,并行单因素分析与探索性多变量建模评估复发下垂相关因素。
  • 证据等级为III级。

主要发现

  • 患者平均年龄45±9岁。
  • 取出指征包括自身免疫/炎症综合征诱导的佐剂相关和/或乳房假体病相关症状(31%)、假体破裂(24%)、包膜挛缩III-IV级(23%)及美学顾虑(20%)。
  • 最常用皮腺体瓣为外侧瓣(72%),其次为下方瓣(20%)、上方瓣(7%)及双蒂瓣(1%)。
  • 总体并发症率为15%,复发下垂发生率为4%,假性下垂或下移发生率为4%。
  • 复发下垂患者的取出假体体积大于无复发者(p < 0.05),但事件数少,该关联应视为探索性。

关键数值与推荐

  • 复发下垂患者与无复发者相比取出假体体积更大(p < 0.05)。

临床怎么用

  • 假体取出后需自体增容与乳房重塑者,可考虑在乳房固定术中应用皮腺体瓣,优先选用外侧瓣。
  • 对取出假体体积较大的患者,应告知单期自体增容后复发下垂风险可能升高并审慎选择术式。

局限性

  • 为单中心回顾性研究,证据等级III级。
  • 复发下垂事件数少,取出假体体积与复发下垂的关联仅为探索性,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The number of patients requesting breast implant explantation without replacement has increased substantially. Breast deflation and recurrent ptosis are common reconstructive challenges following explantation. Dermoglandular flaps provide an autologous option for volume redistribution during mastopexy while avoiding prosthetic materials. OBJECTIVES: To report a five-year single-center experience using dermoglandular flaps for autologous augmentation during mastopexy after breast implant explantation and explore factors associated with postoperative breast stability. METHODS: This retrospective review involved 75 consecutive patients who underwent implant explantation and mastopexy with dermoglandular flap autoaugmentation between 2019 and 2024. Demographic data, implant characteristics, surgical variables, complications, and outcomes with a mean follow-up of 16 ± 6 months were analyzed. Univariate analysis and exploratory multivariable modeling were performed to assess associations with recurrent ptosis. RESULTS: Mean patient age was 45 ± 9 years. Indications for explantation included autoimmune/inflammatory syndrome induced by adjuvants-related and/or breast implant illness-related symptoms (31%), implant rupture (24%), capsular contracture grades III-IV (23%), and esthetic concerns (20%). The most commonly used flaps were lateral dermoglandular flaps (72%), followed by inferior (20%), superior (7%), and bipedicled flaps (1%). The overall complication rate was 15%. Recurrent ptosis occurred in 4% of patients and pseudoptosis or bottoming-out in occurred in 4%. Patients with recurrent ptosis had larger explanted implant volumes compared with those without recurrence (p < 0.05). Given the low number of events, this association should be interpreted as exploratory. CONCLUSIONS: Dermoglandular flaps appear to be a safe and versatile option for autologous augmentation and breast reshaping during implant removal, with acceptable complication rates and satisfactory medium-term stability. Larger explanted implant volumes may be associated with an increased risk of recurrent ptosis, highlighting the potential limitations of single-stage autoaugmentation in selected cases. LEVEL OF EVIDENCE: III.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Procikieviez IO, Procikieviez O. Dermoglandular flaps for autologous augmentation during mastopexy after breast implant explantation: A five-year retrospective study. J Plast Reconstr Aesthet Surg. 2026. PMID: 42501420. doi:10.1016/j.bjps.2026.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。